DEXCOM, INC. | MedPath

Dexcom Advances Diabetes Management with 15-Day CGM Sensor and Expanded Type 2 Applications

2 months ago

• Dexcom's new 15-day continuous glucose monitor demonstrates 8% mean absolute relative difference, positioning it as the most accurate CGM on the market while awaiting FDA clearance expected in the second half of 2023. • Tandem Diabetes Care's Control-IQ+ algorithm for Type 2 diabetes showed significant clinical benefits in a pivotal trial, with patients experiencing a 0.9% reduction in A1C and 16% improvement in time spent in target blood sugar range. • Healthcare provider survey across six countries revealed strong support for CGM as standard care for Type 2 diabetes patients, with 96% of providers endorsing CGM use for those taking multiple daily insulin injections.

FDA Clears Tandem's Control-IQ+ Algorithm for Type 2 Diabetes Management

3 months ago

• Tandem Diabetes Care has received FDA clearance for its Control-IQ+ algorithm, expanding automated insulin delivery system access to all Type 2 diabetes patients using insulin pumps. • The expanded indication significantly increases Tandem's market reach, with the technology compatible with both t:slim X2 tubed pump and Tandem Mobi devices, more than doubling their U.S. addressable market. • Clinical validation data from a 300-person randomized controlled trial supporting the FDA decision will be presented at the upcoming International Conference on Advanced Technologies & Treatments for Diabetes.

Insulet's Omnipod 5 Demonstrates Significant HbA1c Reduction in Type 2 Diabetes Study

3 months ago

• A JAMA-published study reveals Omnipod 5 automated insulin delivery system reduced HbA1c levels from 8.2% to 7.4% in adults with type 2 diabetes over 13 weeks. • The clinical trial, involving 305 adults aged 18-75 years, evaluated the first FDA-cleared automated insulin delivery system for both type 1 and type 2 diabetes. • The study included a diverse patient population and demonstrated the safety and efficacy of automated insulin delivery as a treatment option for type 2 diabetes patients.